Urolog. pro Praxi, 2007; 8(5): 211-216

Diagnostic and treatment of overactive bladder

MUDr. Radovan Vrtal Ph.D, MUDr. Aleš Vidlář, doc. MUDr. Vladimír Študent Ph.D
Urologická klinika FN a LF UP v Olomouci

Overactive bladder is not malignant disease, but from the point of view of patients complaints and quality of life it is very serious problem.This state of the art article inform about some news in diagnostics and treatment patients with OAB.

Keywords: hyperaktivity, incontinence, urodynamics, urgency, frequency

Published: October 23, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrtal R, Vidlář A, Študent V. Diagnostic and treatment of overactive bladder. Urol. praxi. 2007;8(5):211-216.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Cardozo L, Fall M et all: The standardization of terminology of lower urinary tract function: Report from the Standardization Subcommittee of the ICS. Am J Obstet Gynecol 2002, 187 (1): 116-126. Go to original source... Go to PubMed...
    2. Abrams P, Hanno P, Wein A: Overactive bladder and painful bladder syndrome: There need not be confusion. Neurourol Urodyn 2005c, 24: 149-150. Go to original source... Go to PubMed...
    3. Cartwright R, Cardozo L: Transdermal oxybutynin: sticking to the facts. Eur. Urol, 51 (4), 2007, 907-914. Go to original source... Go to PubMed...
    4. Hashim H, Abrams P: Is the bladder a reliable witness for predicting detrusor overactivity? J Urol:, 2006, 175 (1) 191-4. Go to original source... Go to PubMed...
    5. Chapple Ch et all. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the stars trial, Eur Urol 2005, 48 (3): 464-470. Go to original source... Go to PubMed...
    6. Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F, Khullar V, Versi E. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005 Aug; 95 (3): 335-340. Go to original source... Go to PubMed...
    7. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuskarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol, 2005, 48, 5-26. Go to original source... Go to PubMed...
    8. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study, BJU Int, 2001, 87, 760-766. Go to original source... Go to PubMed...
    9. Smith CP, Chancellor MB: Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol, 2004, 171: 2128-2137. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.